ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Vinceanna
|
221 |
80K |
11 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
221
|
80K
|
11
|
|
ASX - By Stock
|
PER |
Re:
CD49d promotes disease progression in chronic lymphocytic leukemia
|
|
Vinceanna
|
37 |
11K |
9 |
05/10/21 |
05/10/21 |
ASX - By Stock
|
37
|
11K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics appoints new Non-Executive Director
|
|
Vinceanna
|
34 |
10K |
5 |
04/10/21 |
04/10/21 |
ASX - By Stock
|
34
|
10K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics appoints new Non-Executive Director
|
|
Vinceanna
|
34 |
10K |
8 |
04/10/21 |
04/10/21 |
ASX - By Stock
|
34
|
10K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Vinceanna
|
221 |
80K |
15 |
02/10/21 |
02/10/21 |
ASX - By Stock
|
221
|
80K
|
15
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Vinceanna
|
221 |
80K |
16 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
221
|
80K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Vinceanna
|
221 |
80K |
16 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
221
|
80K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
10 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
13 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: New data supports ATL1102s broader clinical potential
|
|
Vinceanna
|
66 |
24K |
22 |
25/09/21 |
25/09/21 |
ASX - By Stock
|
66
|
24K
|
22
|
|
ASX - By Stock
|
PER |
Re:
Anp at world muscle society
|
|
Vinceanna
|
42 |
11K |
16 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
42
|
11K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Ann: New data supports ATL1102s broader clinical potential
|
|
Vinceanna
|
66 |
24K |
23 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
66
|
24K
|
23
|
|
ASX - By Stock
|
PER |
Re:
Anp at world muscle society
|
|
Vinceanna
|
42 |
11K |
17 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
42
|
11K
|
17
|
|
ASX - By Stock
|
PER |
Re:
Anp at world muscle society
|
|
Vinceanna
|
42 |
11K |
39 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
42
|
11K
|
39
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present new proteomics data at WMS Congress 2021
|
|
Vinceanna
|
108 |
37K |
14 |
20/09/21 |
20/09/21 |
ASX - By Stock
|
108
|
37K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
11 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Anp at world muscle society
|
|
Vinceanna
|
42 |
11K |
11 |
16/09/21 |
16/09/21 |
ASX - By Stock
|
42
|
11K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
6 |
09/09/21 |
09/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
6
|
|
Charts
|
PER |
Re:
Chart
|
|
Vinceanna
|
5.9K |
2.3M |
8 |
08/09/21 |
08/09/21 |
Charts
|
5.9K
|
2.3M
|
8
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
16 |
07/09/21 |
07/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
6 |
04/09/21 |
04/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Vinceanna
|
1.0K |
365K |
15 |
04/09/21 |
04/09/21 |
ASX - By Stock
|
1.0K
|
365K
|
15
|
|
Charts
|
PER |
Re:
Chart
|
|
Vinceanna
|
5.9K |
2.3M |
4 |
30/08/21 |
30/08/21 |
Charts
|
5.9K
|
2.3M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Pfizer takeover of CD47 blocking Co.
|
|
Vinceanna
|
41 |
13K |
9 |
29/08/21 |
29/08/21 |
ASX - By Stock
|
41
|
13K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Pfizer takeover of CD47 blocking Co.
|
|
Vinceanna
|
41 |
13K |
10 |
28/08/21 |
28/08/21 |
ASX - By Stock
|
41
|
13K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: Appendix 4E and Full Year Statutory Accounts
|
|
Vinceanna
|
42 |
12K |
22 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
42
|
12K
|
22
|
|
ASX - By Stock
|
PER |
Re:
Ann: Appendix 4E and Full Year Statutory Accounts
|
|
Vinceanna
|
42 |
12K |
13 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
42
|
12K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Pfizer takeover of CD47 blocking Co.
|
|
Vinceanna
|
41 |
13K |
20 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
41
|
13K
|
20
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Vinceanna
|
174 |
47K |
4 |
21/08/21 |
21/08/21 |
ASX - By Stock
|
174
|
47K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Vinceanna
|
60 |
15K |
11 |
18/08/21 |
18/08/21 |
ASX - By Stock
|
60
|
15K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Vinceanna
|
60 |
15K |
4 |
18/08/21 |
18/08/21 |
ASX - By Stock
|
60
|
15K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Vinceanna
|
60 |
15K |
24 |
18/08/21 |
18/08/21 |
ASX - By Stock
|
60
|
15K
|
24
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Vinceanna
|
60 |
15K |
17 |
16/08/21 |
16/08/21 |
ASX - By Stock
|
60
|
15K
|
17
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Vinceanna
|
174 |
47K |
19 |
15/08/21 |
15/08/21 |
ASX - By Stock
|
174
|
47K
|
19
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Vinceanna
|
174 |
47K |
22 |
14/08/21 |
14/08/21 |
ASX - By Stock
|
174
|
47K
|
22
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Vinceanna
|
174 |
47K |
14 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
174
|
47K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
2 |
11/08/21 |
11/08/21 |
ASX - By Stock
|
105
|
36K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
10 |
11/08/21 |
11/08/21 |
ASX - By Stock
|
105
|
36K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Another Pinto-Mariz paper
|
|
Vinceanna
|
3 |
1.6K |
14 |
10/08/21 |
10/08/21 |
ASX - By Stock
|
3
|
1.6K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
20 |
08/08/21 |
08/08/21 |
ASX - By Stock
|
105
|
36K
|
20
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
14 |
05/08/21 |
05/08/21 |
ASX - By Stock
|
105
|
36K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
8 |
04/08/21 |
04/08/21 |
ASX - By Stock
|
105
|
36K
|
8
|
|
Charts
|
PER |
Re:
Chart
|
|
Vinceanna
|
5.9K |
2.3M |
22 |
02/08/21 |
02/08/21 |
Charts
|
5.9K
|
2.3M
|
22
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
27 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
105
|
36K
|
27
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Vinceanna
|
105 |
36K |
21 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
105
|
36K
|
21
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Vinceanna
|
287 |
92K |
17 |
24/07/21 |
24/07/21 |
ASX - By Stock
|
287
|
92K
|
17
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Vinceanna
|
287 |
92K |
18 |
23/07/21 |
23/07/21 |
ASX - By Stock
|
287
|
92K
|
18
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Vinceanna
|
287 |
92K |
16 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
287
|
92K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Vinceanna
|
287 |
92K |
32 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
287
|
92K
|
32
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Vinceanna
|
287 |
92K |
25 |
20/07/21 |
20/07/21 |
ASX - By Stock
|
287
|
92K
|
25
|
|